Systems Complement the Beckman Coulter Cell Analysis Portfolio

Orange County, Calif. — Beckman Coulter, Inc., has entered into a strategic alliance with CaridianBCT, under the terms of which Beckman Coulter will market CaridianBCT cell therapy products in specific, targeted markets.

CaridianBCT and Beckman Coulter will launch CaridianBCT’s Quantum Cell Expansion System, a closed system that automates the cell expansion process, along with marketing CaridianBCT’s COBE* 2991 Cell Processor, a system that washes and concentrates cell populations, and the Elutra* Cell Separation System, which purifies cell populations via elutriation.

Adding the Quantum, Elutra and COBE 2991 systems to the Beckman Coulter line of products for cell sorting, cellular analysis and characterization will enable the company to provide pharmaceutical companies, research institutes and clinical trial organizations with a full line of cellular discovery systems.

“Beckman Coulter is pleased to have CaridianBCT as a strategic partner and values their expertise in cell processing and sterile, closed systems,” said Cynthia Collins, group vice president of Cellular Analysis at Beckman Coulter. “We are committed to being the leader in cell therapy tools, and with the addition of these three products to our portfolio of cell sorters, flow cytometers and reagents, we now provide an even wider selection of tools for cell therapy.”

“CaridianBCT has been enabling cell therapy applications around the world for over 30 years with proven systems that collect, separate, wash and concentrate human cells,” said Tom Jordan, senior vice president of Therapeutic Systems at CaridianBCT. “We are confident that Beckman Coulter’s broad market reach and product portfolio, coupled with our innovative systems, will further advance the field of cell therapy.”

CaridianBCT will retain the distribution rights to these cell therapy products in other market segments including commercial cell therapy developers, cell therapy contract manufacturing organizations, the veterinary market, and the cord-blood bank and blood bank markets.

About Beckman Coulter, Inc.

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests. More than 200,000 Beckman Coulter systems operate in laboratories around the world, supplying critical information for improving patient health and reducing the cost of care. Recurring revenue, consisting of consumable supplies (including reagent test kits), service and operating-type lease payments, represent about 80 percent of the company’s 2009 revenue of $3.3 billion. For more information, visit www.beckmancoulter.com.

About CaridianBCT

CaridianBCT is the leading global provider of innovative technologies and services specializing in automated blood collections, therapeutic apheresis and cell therapy systems, whole blood processes and pathogen reduction technologies. The company serves patients through its commitment “For Better Blood and Better Lives” by developing and commercializing products that serve global customers in the blood banking, therapeutic apheresis and transfusion medicine industries. For more information, visit www.caridianbct.com.

*Elutra and COBE are registered trademarks of CaridianBCT.

Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc